Leticia Toledo‐Sherman

1.8k total citations
21 papers, 416 citations indexed

About

Leticia Toledo‐Sherman is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Infectious Diseases. According to data from OpenAlex, Leticia Toledo‐Sherman has authored 21 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 2 papers in Infectious Diseases. Recurrent topics in Leticia Toledo‐Sherman's work include Genetic Neurodegenerative Diseases (8 papers), Mitochondrial Function and Pathology (6 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Leticia Toledo‐Sherman is often cited by papers focused on Genetic Neurodegenerative Diseases (8 papers), Mitochondrial Function and Pathology (6 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Leticia Toledo‐Sherman collaborates with scholars based in United States, Italy and United Kingdom. Leticia Toledo‐Sherman's co-authors include Celia Dominguez, Eugen Deretey, Peter R. Redden, Ignacio Muñoz-Sanjuán, Jin‐Rui Dai, Ruhong Zhou, Leili Zhang, Hongsuk Kang, Robert E. Pacifici and Binquan Luan and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Analytical Chemistry.

In The Last Decade

Leticia Toledo‐Sherman

21 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leticia Toledo‐Sherman United States 14 273 96 46 41 40 21 416
Chunyang Jin United States 14 310 1.1× 173 1.8× 16 0.3× 37 0.9× 16 0.4× 47 579
Sijie Huang China 13 550 2.0× 304 3.2× 17 0.4× 72 1.8× 63 1.6× 26 738
Anjli Venkateswaran United States 7 305 1.1× 59 0.6× 19 0.4× 19 0.5× 22 0.6× 7 609
R. Benjamin Free United States 20 748 2.7× 426 4.4× 19 0.4× 44 1.1× 110 2.8× 57 962
Krishna Praneeth Kilambi United States 9 278 1.0× 21 0.2× 27 0.6× 67 1.6× 97 2.4× 10 493
Andrew D. Gribble United Kingdom 14 362 1.3× 177 1.8× 16 0.3× 39 1.0× 37 0.9× 20 674
Shannon M. Walsh United States 11 232 0.8× 81 0.8× 86 1.9× 16 0.4× 30 0.8× 13 663
Anke C. Schiedel Germany 21 713 2.6× 272 2.8× 17 0.4× 36 0.9× 115 2.9× 47 1.2k
Brian J. Lavey United States 14 241 0.9× 187 1.9× 15 0.3× 43 1.0× 31 0.8× 19 585
Shifeng Xiao China 17 460 1.7× 94 1.0× 34 0.7× 9 0.2× 39 1.0× 29 719

Countries citing papers authored by Leticia Toledo‐Sherman

Since Specialization
Citations

This map shows the geographic impact of Leticia Toledo‐Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leticia Toledo‐Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leticia Toledo‐Sherman more than expected).

Fields of papers citing papers by Leticia Toledo‐Sherman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leticia Toledo‐Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leticia Toledo‐Sherman. The network helps show where Leticia Toledo‐Sherman may publish in the future.

Co-authorship network of co-authors of Leticia Toledo‐Sherman

This figure shows the co-authorship network connecting the top 25 collaborators of Leticia Toledo‐Sherman. A scholar is included among the top collaborators of Leticia Toledo‐Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leticia Toledo‐Sherman. Leticia Toledo‐Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cariulo, Cristina, Margherita Verani, Leticia Toledo‐Sherman, et al.. (2023). IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway. Life Science Alliance. 6(10). e202302006–e202302006. 2 indexed citations
2.
Cummings, Jeffrey L., María Isabel González, Martyn C. Pritchard, et al.. (2023). The therapeutic landscape of tauopathies: challenges and prospects. Alzheimer s Research & Therapy. 15(1). 168–168. 31 indexed citations
3.
Colarusso, Stefania, Mauro Cerretani, Antonino Missineo, et al.. (2020). Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction. Bioorganic & Medicinal Chemistry. 28(21). 115738–115738. 20 indexed citations
4.
Harding, Rachel, P. Loppnau, Suzanne Ackloo, et al.. (2019). Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems. Journal of Biological Chemistry. 294(17). 6986–7001. 23 indexed citations
5.
Cariulo, Cristina, Margherita Verani, Raffaele Ingenito, et al.. (2019). Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13. Biochemical and Biophysical Research Communications. 521(3). 549–554. 10 indexed citations
6.
Bresciani, Alberto, Antonino Missineo, Mariana Gallo, et al.. (2017). Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1). Archives of Biochemistry and Biophysics. 631. 31–41. 42 indexed citations
7.
Zhang, Leili, et al.. (2017). Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment. The Journal of Physical Chemistry B. 121(18). 4713–4721. 11 indexed citations
8.
Kang, Hongsuk, Leili Zhang, Payel Das, et al.. (2017). Emerging β-Sheet Rich Conformations in Supercompact Huntingtin Exon-1 Mutant Structures. Journal of the American Chemical Society. 139(26). 8820–8827. 35 indexed citations
9.
Pacifici, Robert E., Leticia Toledo‐Sherman, Mark J. Rose, & Larry Park. (2016). A4 An overview of energy metabolism in huntington’s disease as a therapeutic target. Journal of Neurology Neurosurgery & Psychiatry. 87(Suppl 1). A2.1–A2. 13 indexed citations
10.
Orsatti, Laura, Maria Vittoria Orsale, Fulvia Caretti, et al.. (2015). A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma. Journal of Pharmaceutical and Biomedical Analysis. 107. 426–431. 14 indexed citations
11.
Winkler, Dirk, Maria Beconi, Leticia Toledo‐Sherman, et al.. (2013). Development of LC/MS/MS, High-Throughput Enzymatic and Cellular Assays for the Characterization of Compounds That Inhibit Kynurenine Monooxygenase (KMO). SLAS DISCOVERY. 18(8). 879–889. 11 indexed citations
12.
Beconi, Maria, Dawn Yates, Kathryn A. Lyons, et al.. (2012). Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048. Drug Metabolism and Disposition. 40(12). 2297–2306. 25 indexed citations
13.
Prime, Michael E., Frederick A. Brookfield, Stephen M. Courtney, et al.. (2012). Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease. ACS Medicinal Chemistry Letters. 3(9). 731–735. 19 indexed citations
14.
Toledo‐Sherman, Leticia, et al.. (2005). Frontal Affinity Chromatography with MS Detection of EphB2 Tyrosine Kinase Receptor. 2. Identification of Small-Molecule Inhibitors via Coupling with Virtual Screening. Journal of Medicinal Chemistry. 48(9). 3221–3230. 38 indexed citations
15.
Dai, Jin‐Rui, et al.. (2005). Global Kinase Screening. Applications of Frontal Affinity Chromatography Coupled to Mass Spectrometry in Drug Discovery. Analytical Chemistry. 77(5). 1268–1274. 42 indexed citations
16.
Toledo‐Sherman, Leticia, et al.. (2004). New targets for an old drug. Clinical Proteomics. 1(3-4). 227–234. 5 indexed citations
17.
Dai, Jin‐Rui, et al.. (2004). Frontal Affinity Chromatography with MS Detection of EphB2 Tyrosine Kinase Receptor. 1. Comparison with Conventional ELISA. Journal of Medicinal Chemistry. 47(21). 5094–5100. 19 indexed citations
18.
Toledo‐Sherman, Leticia, Leroi V. DeSouza, Christopher M. Hosfield, et al.. (2004). New targets for an old drug. Clinical Proteomics. 1(1). 45–67. 10 indexed citations
19.
Sucholeiki, Irving, et al.. (2003). Novel magnetic supports for small molecule affinity capture of proteins for use in proteomics. Molecular Diversity. 8(1). 9–19. 9 indexed citations
20.
Toledo‐Sherman, Leticia, et al.. (2002). High-throughput virtual screening for drug discovery in parallel.. PubMed. 5(3). 414–21. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunyang Jin Breakdown of academic impact, for papers by Sijie Huang Breakdown of academic impact, for papers by Anjli Venkateswaran Breakdown of academic impact, for papers by R. Benjamin Free Breakdown of academic impact, for papers by Krishna Praneeth Kilambi Breakdown of academic impact, for papers by Andrew D. Gribble Breakdown of academic impact, for papers by Shannon M. Walsh Breakdown of academic impact, for papers by Anke C. Schiedel Breakdown of academic impact, for papers by Brian J. Lavey Breakdown of academic impact, for papers by Shifeng Xiao
Rankless by CCL
2026